Glioblastoma

Malignant gliomas are the most common primary malignant brain tumors with glioblastoma multiforme (GBM) being associated with the worst prognosis. Although GBM is rare tumor with global incidence of less than 10 per 100,000 people it is still a deadly disease. Worldwide, malignant gliomas account for 238,000 new cases of brain tumor and 174,000 deaths annually.1 Patients usually have a median survival of approximately 15 months from the diagnosis.2,3
Visualization of malignant gliomas

Over the last decade, a range of different treatments were investigated with very limited success. Surgery is the principal component of standard care.3 The extent of GBM resection depends upon the site and eloquence of the brain area involved. Tumors that resides in sites like eloquent cortex, brain stem or basal ganglia are not amenable to surgical intervention and these patients usually have worse prognosis. The surgical success is limited due to the invasive growth of GBM and the difficulty to resect with an sufficient safety margin.5 Chemo- and radiotherapy have limited effectivity dure to early resistance and accumulation of side effects.

GBM remains incurable due to its heterogeneity and complex pathogenesis. More research efforts will in future help improve treatment options in the fight against the disease.

Final Gliolan design_Rey

Referrence:

  1.  Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893–2917.
  2. Stupp R et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459–466.
  3. Weller M et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15(9): e395–e403.
  4. Ohka F et al. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int, 2012, 878425.
  5. Claes A et al. Diffuse glioma growth: A guerilla war. Acta Neuropathol 2007;114(5):443–458.